Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:FLGC NASDAQ:RENB NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$1.46+1.7%$1.58$1.10▼$3.89$52.77M-0.956,641 shs4,210 shsFLGCFlora Growth$0.51-13.3%$0.65$0.42▼$2.11$13.28M1.97172,440 shs428,700 shsRENBRenovaro$0.26+1.2%$0.32$0.25▼$2.10$43.98M0.541.35 million shs571,136 shsUNCYUnicycive Therapeutics$4.20-3.2%$5.70$2.02▼$11.00$54.86M1.89518,824 shs373,220 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+1.75%+1.04%-7.62%-24.02%-58.43%FLGCFlora Growth-13.32%-17.13%-14.23%-19.05%-49.00%RENBRenovaro+1.17%-16.32%-7.45%-23.04%-64.59%UNCYUnicycive Therapeutics-3.23%-13.76%-9.48%-35.59%-3.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANLAdlai Nortye1.7434 of 5 stars3.05.00.00.00.00.00.0FLGCFlora Growth2.9898 of 5 stars3.35.00.00.03.30.80.6RENBRenovaro0.9234 of 5 stars0.03.00.00.00.63.30.6UNCYUnicycive Therapeutics2.3603 of 5 stars3.72.00.00.01.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.00Hold$9.00518.56% UpsideFLGCFlora Growth 2.50Moderate Buy$4.00684.31% UpsideRENBRenovaro 0.00N/AN/AN/AUNCYUnicycive Therapeutics 3.33Buy$60.001,328.57% UpsideCurrent Analyst Ratings BreakdownLatest FLGC, UNCY, ANL, and RENB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025ANLAdlai NortyeHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$90.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M10.74N/AN/A$0.69 per share2.11FLGCFlora Growth$59.51M0.19N/AN/A$0.31 per share1.65RENBRenovaroN/AN/AN/AN/A$0.89 per shareN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/A$0.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/A8/8/2025 (Estimated)FLGCFlora Growth-$15.91M-$0.98N/AN/AN/A-24.85%-216.49%-45.56%8/11/2025 (Estimated)RENBRenovaro-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%9/29/2025 (Estimated)UNCYUnicycive Therapeutics-$36.73M-$5.10N/AN/AN/AN/A-277.30%-61.53%N/ALatest FLGC, UNCY, ANL, and RENB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025FLGCFlora Growth-$0.06N/AN/AN/A$11.77 millionN/A8/1/2025Q2 2025FLGCFlora Growth-$0.06-$0.11-$0.05-$0.11$11.77 million$14.80 million5/14/2025Q1 2025UNCYUnicycive Therapeutics-$1.40-$0.50+$0.90-$0.05N/AN/A5/13/2025Q1 2025FLGCFlora Growth-$0.01-$0.04-$0.03-$0.04$14.79 million$11.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/AFLGCFlora GrowthN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai Nortye0.021.411.41FLGCFlora Growth0.881.050.67RENBRenovaroN/A0.130.13UNCYUnicycive TherapeuticsN/A1.641.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%FLGCFlora Growth36.01%RENBRenovaro71.41%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/AFLGCFlora Growth12.56%RENBRenovaro21.72%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableFLGCFlora Growth28022.57 million19.73 millionNot OptionableRENBRenovaro20172.12 million134.74 millionOptionableUNCYUnicycive Therapeutics912.64 million11.29 millionNot OptionableFLGC, UNCY, ANL, and RENB HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 31 at 10:00 AM | prnewswire.comUnicycive Therapeutics Inc Ordinary Shares UNCY - MorningstarJuly 30 at 11:55 PM | morningstar.comMUnicycive Therapeutics (NASDAQ:UNCY) Trading Down 6.2% - Here's What HappenedJuly 30 at 3:19 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 28, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 27, 2025 | prnewswire.comUnicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of NephrologyJuly 24, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 23, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 22, 2025 | prnewswire.comUNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. ...July 19, 2025 | gurufocus.comUNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law FirmJuly 19, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 17, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 14, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 12, 2025 | prnewswire.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | finanznachrichten.deUnicycive Therapeutics Regains Compliance with Nasdaq Listing Standards Following Share Price RecoveryJuly 8, 2025 | quiverquant.comQUnicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | globenewswire.comUnicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher - Time to Buy?July 8, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 7, 2025 | prnewswire.comUnicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual ConferenceJuly 7, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY - MorningstarJuly 3, 2025 | morningstar.comMINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 2, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonBig Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadBy Gabriel Osorio-Mazilli | July 3, 2025View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadBig 3 Telecom Wars: 2 Solid Showings, 1 Huge Winner in Q2By Leo Miller | July 29, 2025View Big 3 Telecom Wars: 2 Solid Showings, 1 Huge Winner in Q2Goldman, Morgan Stanley, & BofA: Diverging Paths After EarningsBy Sam Quirke | July 21, 2025View Goldman, Morgan Stanley, & BofA: Diverging Paths After EarningsFLGC, UNCY, ANL, and RENB Company DescriptionsAdlai Nortye NASDAQ:ANL$1.46 +0.03 (+1.75%) Closing price 08/1/2025 03:57 PM EasternExtended Trading$1.46 0.00 (0.00%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Flora Growth NASDAQ:FLGC$0.51 -0.08 (-13.32%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.54 +0.03 (+4.90%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.Renovaro NASDAQ:RENB$0.26 +0.00 (+1.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.26 0.00 (-1.35%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.Unicycive Therapeutics NASDAQ:UNCY$4.20 -0.14 (-3.23%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.32 +0.12 (+2.74%) As of 08/1/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
